Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange (symbol ), with a market capitalization of $1.02 billion as of August 2019.[1]
History
In 1995, Jonathan Ross Goodman and Mark Beaudet founded Paladin Labs, the predecessor company to Knight Therapeutics. It launched an IPO in that year at $1.50 per share.[2]
In 2011, Goodman was seriously injured in a cycling accident, forcing him to temporarily relinquish the CEO role to Mark Beaudet.[2] The accident caused serious traumatic brain injury, although Goodman has almost fully recovered.[3] Also in 2011, Paladin offered to buy Afexa Life Sciences for $57 million, but was outbid by Valeant Pharmaceuticals